cintredekin besudotox + temozolomide

Cintredekin besudotox + temozolomide is a combination therapy investigated primarily for the treatment of malignant gliomas, especially glioblastoma multiforme. Cintredekin besudotox is a recombinant fusion protein composed of human interleukin 13 (IL-13) linked to a truncated form of Pseudomonas exotoxin A (PE38QQR). It selectively targets and binds to IL13 receptor alpha2, which is overexpressed on malignant glioma cells but minimally present in normal brain tissue. Upon binding, the exotoxin moiety enters the tumor cell and induces cytotoxicity by inhibiting protein synthesis, leading to cell death. Temozolomide is an oral alkylating agent that methylates DNA at the O6 and N7 positions of guanine, resulting in DNA damage and apoptosis in rapidly dividing tumor cells. The combination has been studied with convection-enhanced delivery (CED) for cintredekin besudotox directly into brain tissue after surgical resection, followed by standard external beam radiation therapy with or without concurrent oral temozolomide. The rationale behind this regimen is to maximize local cytotoxic effects against residual tumor cells while leveraging systemic chemotherapy's broader anti-tumor activity[2][3][4][7].

Other names

hIL-13-PEhIL13-PEhIL 13-PECB